BioInvent International AB (publ) 45,54
BioInvent International AB (publ), a clinical-stage company, discovers, researches, and develops immuno-modulatory antibodies for the treatment of cancer in Sweden, rest of Europe, the United States, Japan, and internationally. Its lead drug candidate is BI-1206, a monoclonal antibody targeting CD32b, which is in Phase I/IIa clinical trials in patients with B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia. The company is also developing cancer-associated regulatory T cells which modulate the immune system; and BI-1808 and BI-1910, an anti-TNFR2 antibody for the treatment of solid tumors and cutaneous T-cell lymphoma (CTCL). It has a strategic collaboration with Pfizer Inc. for the development of antibodies against tumour-associated myeloid cells; partnership and collaboration with Transgene to co-develop multi-functional oncolytic viruses for treatment of solid tumors; and a collaboration agreement with SkylineDx to characterize the gene expression and immunological signatures in tumors of patients pre-and post-treatment with BI-1206. The Company was incorporated in 1996 and is headquartered in Lund, Sweden. Læs mere
Kr. 2,5B Markedsværdi
Kr. 113M Omsætning
Bioteknologi Industri
Sverige Hjemland
bioinvent.com Hjemmeside